Why the study?
Do emerging LDLR-independent, RNA-based, and gene-editing therapies effectively reduce LDL-C concentrations in patients with homozygous familial hypercholesterolemia?
Do emerging LDLR-independent, RNA-based, and gene-editing therapies effectively reduce LDL-C concentrations in patients with homozygous familial hypercholesterolemia?
Answers are grounded in this paper and cite their sources.
LDLR-independent therapies like evinacumab, alongside emerging siRNA and gene-editing strategies targeting PCSK9 and ANGPTL3, offer substantial and durable LDL-C reductions for patients with homozygous familial hypercholesterolemia who are refractory to conventional treatments.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Robert S. Rosenson (2026) conducted an editorial in Homozygous familial hypercholesterolemia (HoFH). ANGPTL3-targeted and gene-editing lipid-lowering therapies (e.g., evinacumab, zodasiran, lomitapide, VERVE-102, CTX 310) vs. Conventional lipid-lowering therapies (statins, ezetimibe, PCSK9 inhibitors) was evaluated on Reduction in low-density lipoprotein cholesterol (LDL-C).
Synapse has enriched 10 related papers. Consider them for comparative context: